Veracyte Inc. has announced the publication of two studies demonstrating the potential of the Afirma GRID (Genomic Resource for Intelligent Discovery) research tool in advancing thyroid nodule evaluation. These studies, published in Frontiers in Endocrinology and Surgery, used Afirma GRID's whole-transcriptome-derived platform to analyze molecular data from thyroid nodules and develop gene expression signatures that may provide enhanced prognostic information prior to surgery. The findings suggest that such signatures could potentially serve as preoperative predictive tools for high-risk features in thyroid cancer, aiding in recurrence risk stratification and surgical planning. However, the authors note that further validation studies are needed before these signatures can be used in clinical practice. The results of the studies have already been published.